[go: up one dir, main page]

IS2672B - Asíþrómýsín lyfjaskammtaform með minni hliðarverkanir - Google Patents

Asíþrómýsín lyfjaskammtaform með minni hliðarverkanir

Info

Publication number
IS2672B
IS2672B IS7464A IS7464A IS2672B IS 2672 B IS2672 B IS 2672B IS 7464 A IS7464 A IS 7464A IS 7464 A IS7464 A IS 7464A IS 2672 B IS2672 B IS 2672B
Authority
IS
Iceland
Prior art keywords
azispromycin
dosage forms
side effects
minor side
minor
Prior art date
Application number
IS7464A
Other languages
English (en)
Other versions
IS7464A (is
Inventor
Leah Elizabeth Appel
Marshall David Crew
Dwayne Thomas Friesen
Timothy Arthur Hagen
Scott Max Herbig
Julian Belknap Lo
David Keith Lyon
Scott Baldwin Mccray
Avinash Govind Thombre
James Blair West
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34468055&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2672(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IS7464A publication Critical patent/IS7464A/is
Publication of IS2672B publication Critical patent/IS2672B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
IS7464A 2003-12-04 2004-09-20 Asíþrómýsín lyfjaskammtaform með minni hliðarverkanir IS2672B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52708403P 2003-12-04 2003-12-04
US10/763,340 US6984403B2 (en) 2003-12-04 2004-01-23 Azithromycin dosage forms with reduced side effects
PCT/IB2004/001654 WO2005053650A1 (en) 2003-12-04 2004-05-14 Azithromycin dosage forms with reduced side effects

Publications (2)

Publication Number Publication Date
IS7464A IS7464A (is) 2005-06-05
IS2672B true IS2672B (is) 2010-09-15

Family

ID=34468055

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7464A IS2672B (is) 2003-12-04 2004-09-20 Asíþrómýsín lyfjaskammtaform með minni hliðarverkanir

Country Status (36)

Country Link
US (4) US6984403B2 (is)
EP (1) EP1537859B1 (is)
JP (2) JP4602711B2 (is)
KR (1) KR100906290B1 (is)
AR (1) AR045630A1 (is)
AT (1) ATE407663T1 (is)
BR (1) BRPI0403935B8 (is)
CA (1) CA2467611C (is)
CL (1) CL2004001501A1 (is)
CR (1) CR7500A (is)
CY (1) CY1108486T1 (is)
DE (1) DE602004016444D1 (is)
DK (1) DK1537859T3 (is)
DO (1) DOP2004000994A (is)
EA (1) EA010110B1 (is)
ES (1) ES2312929T3 (is)
GE (1) GEP20074056B (is)
HK (1) HK1080367B (is)
HR (1) HRP20040865A2 (is)
IL (1) IL164165A (is)
IS (1) IS2672B (is)
MA (1) MA27848A1 (is)
MX (1) MXPA04009424A (is)
NL (1) NL1026315C2 (is)
NO (1) NO20043903L (is)
NZ (1) NZ535464A (is)
OA (1) OA12858A (is)
PA (1) PA8611501A1 (is)
PE (1) PE20050573A1 (is)
PL (2) PL1537859T3 (is)
PT (1) PT1537859E (is)
RS (1) RS84704A (is)
SI (1) SI1537859T1 (is)
TW (1) TWI351969B (is)
UY (1) UY28509A1 (is)
WO (1) WO2005053650A1 (is)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2163504T5 (es) † 1994-05-06 2008-05-16 Pfizer Inc. Formas de dosificacion de liberacion controlada de azitromicina.
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
EP2368553B1 (en) 2003-04-08 2014-12-31 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
WO2005053652A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
CN1889932A (zh) * 2003-12-04 2007-01-03 辉瑞产品公司 制备药用多颗粒的方法
CA2561855A1 (en) * 2004-04-12 2005-10-20 Pfizer Products Inc. Taste-masked drugs in rupturing multiparticulates
ES2653568T3 (es) 2004-06-12 2018-02-07 Collegium Pharmaceutical, Inc. Formulaciones de fármacos para la prevención del abuso
EP1782816B1 (en) * 2004-07-02 2011-10-19 Wakamoto Pharmaceutical Co., Ltd. Water-based medicinal composition containing azithromycin and method of preparing the same
JP4713104B2 (ja) * 2004-08-04 2011-06-29 ファイザー株式会社 アジスロマイシン類を有効成分とする苦味が抑制された安定な組成物
US20060193908A1 (en) * 2004-11-09 2006-08-31 Burnside Beth A Extended release formulations of poorly soluble antibiotics
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
CN101340882B (zh) * 2005-12-22 2015-02-11 大塚制药株式会社 含有药物的蜡基质粒子的制造方法、用于该方法的挤出机、及含有西洛他唑的缓释制剂
EP2724704A1 (en) * 2005-12-22 2014-04-30 Otsuka Pharmaceutical Co., Ltd. Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
EP2023721A2 (en) * 2006-06-05 2009-02-18 Auspex Pharmaceuticals Inc. Preparation and utility of substituted erythromycin analogs
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
EP2091519B1 (en) * 2006-11-30 2015-06-24 Bend Research, Inc Multiparticulates of spray-coated drug and polymer on a meltable core
US11116728B2 (en) 2006-11-30 2021-09-14 Bend Research, Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
JP5162134B2 (ja) * 2007-01-22 2013-03-13 愛媛県 機能性材料の製造方法、機能性材料、シート状構造体、及び衛生製品
US10888521B2 (en) * 2007-03-02 2021-01-12 Farnam Companies, Inc. Sustained release compositions using wax-like materials
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
EP3263571B2 (en) 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Crystal form of (r)-n-methylnaltrexone bromide and uses thereof
JP5469593B2 (ja) 2007-03-29 2014-04-16 ワイス・エルエルシー 末梢性オピオイド受容体アンタゴニストおよびその使用
DE102007026550A1 (de) * 2007-06-08 2008-12-11 Bayer Healthcare Ag Extrudate mit verbesserter Geschmacksmaskierung
DE102007034155A1 (de) * 2007-07-21 2009-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Vorrichtung mit mindestens einer Verpackungseinheit mit einem zur Radiofrequenz-Identifikation dienenden RFID-Chip und Verfahren dazu
CA2711807A1 (en) 2008-01-08 2009-07-16 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
CN101959892B (zh) * 2008-02-06 2014-01-08 普罗热尼奇制药公司 (r),(r)-2,2’-二-甲基纳曲酮的制备和用途
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
AU2009274137B2 (en) * 2008-07-21 2013-10-31 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
ES2564797T3 (es) 2009-08-19 2016-03-29 Eisai R&D Management Co., Ltd. Composición farmacéutica con contenido en un derivado de quinolina
EP2314286A1 (de) * 2009-10-21 2011-04-27 Ratiopharm GmbH Schmelzgranuliertes Cinacalcet
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
WO2011125075A2 (en) 2010-04-08 2011-10-13 Fdc Limited A novel gastroretentive delivery of macrolide
BR112013020533A2 (pt) 2011-02-11 2016-10-18 Zs Pharma Inc silicato de zircônio microporoso para o tratamento de hipercalemia
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
US9943637B2 (en) 2012-06-11 2018-04-17 ZS Pharma, Inc. Microporous zirconium silicate and its method of production
AU2013290141A1 (en) 2012-07-11 2015-02-05 Alvaro F. Guillem Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia
US8877255B2 (en) 2012-10-22 2014-11-04 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
US10695365B2 (en) 2012-10-22 2020-06-30 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
KR20160096178A (ko) * 2013-12-10 2016-08-12 제트에스 파마, 인코포레이티드 리튬 공동 투여 없이 고칼륨혈증을 치료하기 위한 규산지르코늄
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
RS65049B1 (sr) * 2015-02-25 2024-02-29 Eisai R&D Man Co Ltd Metoda za suzbijanje gorčine derivata kinolina
CA2978322A1 (en) * 2015-03-10 2016-09-15 Lumos Pharma, Inc. Cyclocreatine microsuspension
EP3307275B1 (en) 2015-06-10 2021-05-26 Piedmont Animal Health Inc. Injectable antibiotic formulations and use thereof
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
ES2887426T3 (es) 2015-08-20 2021-12-22 Eisai R&D Man Co Ltd Lenvatinib combinado con etopósido e ifosfamida para su uso en el tratamiento de un tumor
JP7136763B2 (ja) 2016-03-15 2022-09-13 エイサー セラピューティクス インコーポレーテッド フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US10940163B2 (en) * 2017-02-02 2021-03-09 Mcmaster University Bicarbonate as a potentiator for antimicrobial agents
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
CR20200419A (es) 2018-02-18 2020-10-23 G & G Biotechnology Ltd Implantes con adhesión mejorada a la cubierta
EP3829640A4 (en) 2018-08-01 2022-05-25 McMaster University Methods for inhibiting microbe growth
CN111643455A (zh) * 2020-06-22 2020-09-11 健民药业集团股份有限公司 一种阿奇霉素缓释干混悬剂及其制备方法
WO2022220669A1 (es) * 2021-04-16 2022-10-20 Garcia Perez Miguel Angel Combinación sólida oral para el tratamiento de infección por virus
CN114699386B (zh) * 2022-04-14 2023-05-23 深圳职业技术学院 阿奇霉素组合物及其制备方法

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3590A (en) * 1844-05-17 Rule or measure
US165563A (en) * 1875-07-13 Improvement in snow-plows
US6650A (en) * 1849-08-14 Edmund blunt
US228357A (en) * 1880-06-01 Walter m
US14951A (en) * 1856-05-27 Boot-tree
US25342A (en) * 1859-09-06 Justus k
US190365A (en) * 1877-05-01 Improvement in running-gear for vehicles
US26851A (en) * 1860-01-17 Improvement
US2955956A (en) 1957-05-15 1960-10-11 Morton Salt Co Process and apparatus for coating granules
US4092089A (en) 1974-04-06 1978-05-30 Bayer Aktiengesellschaft Apparatus for the preparation of melt-sprayed spherical phenacetin granules
US4086346A (en) 1974-04-06 1978-04-25 Bayer Aktiengesellschaft Preparation of melt-sprayed spherical phenacetin granules
US4053264A (en) 1976-01-30 1977-10-11 United Technologies Corporation Apparatus for making metal powder
US4293570A (en) 1979-04-02 1981-10-06 Chimicasa Gmbh Process for the preparation of sweetener containing product
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4340582A (en) 1981-01-15 1982-07-20 Abbott Laboratories Erythromycin base tablets
SI8110592A8 (en) 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
PH19293A (en) 1982-11-15 1986-03-04 Pfizer Epimeric azahomoerythromycin,pharmaceutical composition containing the same and method of use thereof
US4675140A (en) 1984-05-18 1987-06-23 Washington University Technology Associates Method for coating particles or liquid droplets
US4874611A (en) 1985-06-20 1989-10-17 The Dow Chemical Company Microencapsulated ant bait
US5019302A (en) 1986-03-12 1991-05-28 Washington University Technology Associates, Inc. Method for granulation
US5100592A (en) 1986-03-12 1992-03-31 Washington University Technology Associated, Inc. Method and apparatus for granulation and granulated product
US5387431A (en) 1991-10-25 1995-02-07 Fuisz Technologies Ltd. Saccharide-based matrix
US5236734A (en) 1987-04-20 1993-08-17 Fuisz Technologies Ltd. Method of preparing a proteinaceous food product containing a melt spun oleaginous matrix
US5456932A (en) 1987-04-20 1995-10-10 Fuisz Technologies Ltd. Method of converting a feedstock to a shearform product and product thereof
RO107257B1 (ro) * 1987-07-09 1993-10-30 Pfizer Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
WO1989002271A1 (en) 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
HRP20020231A2 (en) 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
US5064650A (en) 1988-04-19 1991-11-12 Southwest Research Institute Controlled-release salt sensitive capsule for oral use and adhesive system
US5024842A (en) 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US5160743A (en) 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US4931285A (en) 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5047244A (en) 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
AU655162B2 (en) 1989-11-13 1994-12-08 Nova Pharmaceutical Corporation Lipospheres for controlled delivery of substances
JPH03206039A (ja) * 1990-01-08 1991-09-09 Kyoto Yakuhin Kogyo Kk ニフェジピン持続性製剤
US5084287A (en) 1990-03-15 1992-01-28 Warner-Lambert Company Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat
US5213810A (en) 1990-03-30 1993-05-25 American Cyanamid Company Stable compositions for parenteral administration and method of making same
EP0452862B1 (en) 1990-04-18 1995-07-19 Asahi Kasei Kogyo Kabushiki Kaisha Spherical seed cores, spherical granules and process for production thereof
US5183690A (en) 1990-06-25 1993-02-02 The United States Of America, As Represented By The Secretary Of Agriculture Starch encapsulation of biologically active agents by a continuous process
GB9014646D0 (en) 1990-07-02 1990-08-22 Courtaulds Coatings Holdings Coating compositions
US5194262A (en) 1990-10-22 1993-03-16 Revlon Consumer Products Corporation Encapsulated antiperspirant salts and deodorant/antiperspirants
US5196199A (en) 1990-12-14 1993-03-23 Fuisz Technologies Ltd. Hydrophilic form of perfluoro compounds and method of manufacture
US5292657A (en) 1990-12-31 1994-03-08 Pioneer Hi-Bred International, Inc. Process for preparing rotary disc fatty acid microspheres of microorganisms
US5143662A (en) 1991-02-12 1992-09-01 United States Surgical Corporation Process for preparing particles of bioabsorbable polymer
US5707546A (en) * 1991-06-17 1998-01-13 Rio Linda Chemical Co., Inc. Generation and storage of chlorine dioxide in a non-aqueous medium
US5405617A (en) 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
GB9201857D0 (en) 1992-01-29 1992-03-18 Smithkline Beecham Plc Novel compound
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
DE4214272A1 (de) 1992-05-04 1993-11-11 Nukem Gmbh Verfahren und Vorrichtung zur Herstellung von Mikrokugeln
CA2095776C (en) 1992-05-12 2007-07-10 Richard C. Fuisz Rapidly dispersable compositions containing polydextrose
ES2086229T3 (es) 1992-05-22 1996-06-16 Goedecke Ag Procedimiento para la obtencion de preparados medicinales de accion retardada.
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
SE9201930D0 (sv) 1992-06-24 1992-06-24 Astra Ab Gastric antibacterial treatment
TW271400B (is) 1992-07-30 1996-03-01 Pfizer
US5348758A (en) 1992-10-20 1994-09-20 Fuisz Technologies Ltd. Controlled melting point matrix formed with admixtures of a shearform matrix material and an oleaginous material
US5380473A (en) 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
GB9224855D0 (en) 1992-11-27 1993-01-13 Smithkline Beecham Plc Pharmaceutical compositions
US5569467A (en) 1993-05-15 1996-10-29 Societe De Conseils De Recherches Et D'applications (S.C.R.A.S.) Process for the preparation of microballs and microballs thus obtained
IL109770A0 (en) 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
US5690959A (en) 1993-05-29 1997-11-25 Smithkline Beecham Corporation Pharmaceutical thermal infusion process
US5851553A (en) 1993-09-10 1998-12-22 Fuisz Technologies, Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5597416A (en) 1993-10-07 1997-01-28 Fuisz Technologies Ltd. Method of making crystalline sugar and products resulting therefrom
US5935600A (en) 1993-09-10 1999-08-10 Fuisz Technologies Ltd. Process for forming chewable quickly dispersing comestible unit and product therefrom
WO1995009601A1 (en) 1993-10-01 1995-04-13 The Procter & Gamble Company Use of azithromycin for the treatment of adult periodontitis and topical compositions for this use
US5433951A (en) 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
AT401871B (de) 1994-01-28 1996-12-27 Gebro Broschek Gmbh Verfahren zur herstellung von s(+)-ibuprofen- partikeln mit verbesserten fliesseigenschaften und deren verwendung zur arzneimittelherstellung
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
WO1995025504A1 (en) 1994-03-18 1995-09-28 Pharmavene, Inc. Emulsified drug delivery systems
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
ES2163504T5 (es) * 1994-05-06 2008-05-16 Pfizer Inc. Formas de dosificacion de liberacion controlada de azitromicina.
DE19509807A1 (de) 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5582855A (en) 1994-07-01 1996-12-10 Fuisz Technologies Ltd. Flash flow formed solloid delivery systems
US5556652A (en) 1994-08-05 1996-09-17 Fuisz Technologies Ltd. Comestibles containing stabilized highly odorous flavor component delivery systems
US5601761A (en) 1994-09-26 1997-02-11 The Dow Chemical Company Encapsulated active materials and method for preparing same
US5493044A (en) * 1994-10-20 1996-02-20 Fmc Corporation Process for preparing alkylsilyl or arylsilyl ethers
US5965164A (en) 1994-10-28 1999-10-12 Fuisz Technologies Ltd. Recipient-dosage delivery system
US5683720A (en) 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
US6083430A (en) 1994-10-28 2000-07-04 Fuisz Technologies Ltd. Method of preparing a dosage unit by direct tableting and product therefrom
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
FR2732621B1 (fr) 1995-04-10 1997-06-06 Rhone Poulenc Chimie Perles d'un produit presentant le phenomene de surfusion et leur procede d'obtention
KR100404293B1 (ko) 1995-05-02 2004-02-18 다이쇼 세이야꾸 가부시끼가이샤 경구투여용조성물
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5883103A (en) 1995-06-07 1999-03-16 Shire Laboratories Inc. Oral acyclovir delivery
WO1997002019A1 (en) 1995-06-30 1997-01-23 Baylor University Polyester/carboxylic acid composite materials
EP0784933A3 (en) 1995-10-16 1997-11-26 Leaf, Inc. Extended release of additives in comestible products
US5919489A (en) 1995-11-01 1999-07-06 Abbott Laboratories Process for aqueous granulation of clarithromycin
DE19543633C2 (de) 1995-11-23 2000-08-17 Cognis Deutschland Gmbh Kosmetische und/oder pharmazeutische Zubereitungen
US5705190A (en) 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5916582A (en) * 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
DE19629753A1 (de) 1996-07-23 1998-01-29 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
US6139872A (en) 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
HRP970485A2 (en) 1996-09-13 1998-08-31 Joerg Rosenberg Process for producing solid pharmaceutical forms
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US6190591B1 (en) 1996-10-28 2001-02-20 General Mills, Inc. Embedding and encapsulation of controlled release particles
DE19652257A1 (de) * 1996-12-16 1998-06-18 Lohmann Therapie Syst Lts Einzeln dosierte, bei Kontakt mit Flüssigkeit schnell zerfallende, wirkstoff- und insbesondere aromastoffhaltige, folienförmige Darreichnungsform
US5948407A (en) 1997-03-19 1999-09-07 Shire Laboratories Inc. Oral induction of tolerance to parenterally administered non-autologous polypeptides
US6551616B1 (en) 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6010718A (en) 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
SK282427B6 (sk) 1997-06-11 2002-01-07 Abbott Laboratories Pevná farmaceutická kompozícia s riadeným uvoľňovaním
DE19729487A1 (de) 1997-07-10 1999-01-14 Dresden Arzneimittel Verfahren zur Herstellung von Wirkstoff-Zubereitungen mit kontrollierter Freisetzung aus einer Matrix
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US5851555A (en) 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
US5840334A (en) 1997-08-20 1998-11-24 Fuisz Technologies Ltd. Self-binding shearform compositions
US5869098A (en) 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US5980941A (en) 1997-08-20 1999-11-09 Fuisz Technologies Ltd. Self-binding shearform compositions
IT1294760B1 (it) * 1997-09-03 1999-04-12 Jagotec Ag Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
US6692767B2 (en) 1997-09-19 2004-02-17 Shire Laboratories Inc. Solid solution beadlet
US6013280A (en) 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
IE970731A1 (en) 1997-10-07 2000-10-04 Fuisz Internat Ltd Product and method for the treatment of hyperlipidemia
ZA989763B (en) 1997-11-07 1999-05-07 Novo Nordisk As Pharmaceutical composition comprising levormeloxifene in low dose
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US5891845A (en) 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
DE69825128T3 (de) 1997-12-02 2010-05-06 Pfizer Products Inc., Groton Verwendung von azithromycin zur topischen behandlung von augeninfektionen
PT1037607E (pt) 1997-12-08 2004-07-30 Altana Pharma Ag Nova forma de supositorio compreendendo um composto activo instavel em acido
EP0943341A1 (en) 1998-02-18 1999-09-22 Oscar Gold Procedure to prepare granulated compositions that contain erythromycin macrolides and procedure to prepare pharmaceutical compositions that contain said macrolides
US6270804B1 (en) 1998-04-03 2001-08-07 Biovail Technologies Ltd. Sachet formulations
US6423345B2 (en) 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
JPH11335300A (ja) * 1998-05-20 1999-12-07 Sumitomo Pharmaceut Co Ltd グリセリン脂肪酸エステルを使用した徐放性製剤
FR2779651B1 (fr) 1998-06-16 2001-04-20 Gattefosse Ets Sa Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
US6086920A (en) 1998-08-12 2000-07-11 Fuisz Technologies Ltd. Disintegratable microspheres
US6117452A (en) 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
US6245903B1 (en) 1998-08-21 2001-06-12 Apotex, Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
WO2000026285A1 (en) 1998-10-29 2000-05-11 Penreco Gel compositions
US6165512A (en) 1998-10-30 2000-12-26 Fuisz Technologies Ltd. Dosage forms containing taste masked active agents
RO121408B1 (ro) 1998-11-30 2007-05-30 Teva Pharmaceutical Industries Ltd. Etanolat de azitromicină, procedeu de obţinere şi compoziţii farmaceutice ale acestuia
DE19901683B4 (de) * 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung
DE60042352D1 (de) * 1999-02-10 2009-07-23 Pfizer Prod Inc Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
IN187487B (is) 1999-02-25 2002-05-04 M S Alembic Chemical Works Com
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2793690B1 (fr) 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
BR0014320A (pt) * 1999-09-27 2002-05-28 Sonus Pharma Inc Composições de substâncias terapêuticas solúveis em tocol
ES2299441T3 (es) 1999-12-08 2008-06-01 Pharmacia Corporation Forma en estado solido de celecoxib con biodisponibilidad potenciada.
IL141438A0 (en) 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
KR20010097244A (ko) 2000-04-21 2001-11-08 유충식 위산도 비의존성 고용해도를 갖는 이트라코나졸 함유약학적 조성물 및 그 제조방법
DE60108255T2 (de) 2000-09-22 2005-12-22 Galephar M/F Clarithromycin enthaltende zubereitung mit verlängerter freisetzung
WO2003018031A2 (en) 2001-08-21 2003-03-06 Pfizer Products Inc. Single dose azithromycin for treating respiratory infections
WO2003037304A1 (en) 2001-11-02 2003-05-08 Wockhardt Limited Controlled release compositions for macrolide antimicrobial agents
BR0215262A (pt) 2001-12-20 2004-12-28 Pharmacia Corp Formas de dosagem com liberação sustentada de ordem zero e processo para a fabricação das mesmas
AU2002353316A1 (en) * 2001-12-21 2003-07-09 Pfizer Products Inc. Methods for wet granulating azithromycin
WO2003053416A1 (en) 2001-12-21 2003-07-03 Pfizer Products Inc. Directly compressible formulations of azithromycin
CN1646104A (zh) * 2002-02-01 2005-07-27 辉瑞产品公司 阿齐霉素的干颗粒制剂
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20030187663A1 (en) 2002-03-28 2003-10-02 Truman Michael Mead Broadband frequency translation for high frequency regeneration
GB0214277D0 (en) 2002-06-20 2002-07-31 Biochemie Gmbh Organic compounds
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
ATE421882T1 (de) 2003-07-24 2009-02-15 Pliva Hrvatska D O O Schnellösliches azithromycin in einzeldosisform

Also Published As

Publication number Publication date
JP2005162733A (ja) 2005-06-23
EA010110B1 (ru) 2008-06-30
WO2005053650A1 (en) 2005-06-16
EP1537859A3 (en) 2005-07-06
US20060039988A1 (en) 2006-02-23
CR7500A (es) 2007-09-03
TWI351969B (en) 2011-11-11
US20080015343A1 (en) 2008-01-17
EP1537859B1 (en) 2008-09-10
OA12858A (en) 2006-09-15
PE20050573A1 (es) 2005-09-05
TW200518784A (en) 2005-06-16
IL164165A (en) 2012-01-31
IS7464A (is) 2005-06-05
HK1080367A1 (zh) 2006-04-28
US6984403B2 (en) 2006-01-10
KR20060033851A (ko) 2006-04-20
CA2467611C (en) 2010-03-30
WO2005053650A8 (en) 2005-12-01
BRPI0403935A (pt) 2005-08-09
PA8611501A1 (es) 2005-08-04
JP4602711B2 (ja) 2010-12-22
NL1026315C2 (nl) 2006-01-24
NL1026315A1 (nl) 2005-06-07
PT1537859E (pt) 2008-11-18
EA200401216A1 (ru) 2005-12-29
NZ535464A (en) 2009-03-31
HRP20040865A2 (en) 2006-02-28
SI1537859T1 (sl) 2008-12-31
PL1537859T3 (pl) 2009-01-30
US20060029677A1 (en) 2006-02-09
NO20043903L (no) 2004-11-09
KR100906290B1 (ko) 2009-07-06
IL164165A0 (en) 2005-12-18
CL2004001501A1 (es) 2005-05-13
DK1537859T3 (da) 2008-11-17
CA2467611A1 (en) 2005-06-04
PL379984A1 (pl) 2006-11-27
DE602004016444D1 (de) 2008-10-23
MA27848A1 (fr) 2006-04-03
RS84704A (sr) 2007-02-05
MXPA04009424A (es) 2005-07-26
CY1108486T1 (el) 2014-04-09
EP1537859A2 (en) 2005-06-08
JP2010132700A (ja) 2010-06-17
BRPI0403935B1 (pt) 2018-02-06
UY28509A1 (es) 2005-07-29
DOP2004000994A (es) 2005-06-30
ES2312929T3 (es) 2009-03-01
ATE407663T1 (de) 2008-09-15
US20050123627A1 (en) 2005-06-09
BRPI0403935B8 (pt) 2021-05-25
HK1080367B (zh) 2010-11-05
AR045630A1 (es) 2005-11-02
GEP20074056B (en) 2007-03-12

Similar Documents

Publication Publication Date Title
IS2672B (is) Asíþrómýsín lyfjaskammtaform með minni hliðarverkanir
DE602004017700D1 (de) Transmukosen verabreichung
IS7689A (is) Fjölþátta lyfjaskammtaform
IS7894A (is) Skammtaform með ofnæmisvaka
DE602004030244D1 (de) Itoren
DE602004018130D1 (de) Kaffeeaufbrühvorrichtung
DE602004016801D1 (de) Weglenkungsüberwachung
DE602004018967D1 (de) Amidoacetonitrilderivate
DK1622630T3 (da) P009368epdk1
DE112004000620D2 (de) Struktoguss
DE602004021612D1 (de) Chtungsmassen
DE602004023862D1 (de) Winkelpositionseinstellmechanismus
DE602004021338D1 (de) Gasflüssigkeitsabscheider
FI20031679L (fi) Työnnin
NO20034599D0 (no) Brokonstruksjon
DE60326234D1 (de) Magnetronkathodenanordnung
PT1678290T (pt) Resumo
DE502004010296D1 (de) Chromenonindole
NO20034600L (no) Brokonstruksjon
FI20030355A0 (fi) Avainpesäjärjestely
FI20030791A0 (fi) Temperaturkompenserad förstärkare
DE602004021217D1 (de) Koplanarleiterresonator
DE502004007959D1 (de) Prolinylarylacetamide
DE502004007251D1 (de) En 2-arylpropenalen
DE112004002110D2 (de) Behälter-Deckel-Kombination